GLPwatch
Adlyxin for MASH (metabolic dysfunction-associated steatohepatitis)
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCAdlyxin (lixisenatide) is not FDA-approved for MASH. A systematic review with individual patient data meta-analysis of randomized controlled trials in type 2 diabetes patients found that lixisenatide reduced elevated liver transaminases, which may suggest potential benefits for liver health.
AI summary of the sources below.
| Drug | Adlyxin (lixisenatide) |
|---|---|
| Condition | MASH (metabolic dysfunction-associated steatohepatitis) |
| Approval status | Investigational / off-label |
| Research papers | 1 |
Adlyxin is not FDA-approved for mash (metabolic dysfunction-associated steatohepatitis); the research below reflects investigational or off-label study only.